COVID Bivalent Booster Better vs Omicron Subvariants: Pfizer

Argentina Noticias Noticias

COVID Bivalent Booster Better vs Omicron Subvariants: Pfizer
Argentina Últimas Noticias,Argentina Titulares
  • 📰 Medscape
  • ⏱ Reading Time:
  • 37 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 18%
  • Publisher: 55%

One month after receiving a booster with the bivalent vaccine, those older than 55 had 4x more neutralizing antibodies against these Omicron subvariants compared with people who received the original monovalent vaccine as a booster in a recent study.

by the US Food and Drug Administration for ages 5 years and older. The safety and tolerability profile of the Pfizer/BioNTech bivalent booster remains favorable and similar to the original COVID-19 vaccine, the company reported.

"For example, there may be significant differences between the groups, and the release mentions at least one difference that is of importance: the interval since the last vaccination which often affects the response to subsequent boosting," she said. More researcher results are warranted."These data do not indicate that these differences between the two vaccines translate into a meaningful clinical benefit at a population level," El Sahly said."As we head into the holiday season, we hope these updated data will encourage people to seek out a COVID-19 bivalent booster as soon as they are eligible in order to maintain high levels of protection against the widely circulating Omicron BA.4 and BA.

Hemos resumido esta noticia para que puedas leerla rápidamente. Si estás interesado en la noticia, puedes leer el texto completo aquí. Leer más:

Medscape /  🏆 386. in US

Argentina Últimas Noticias, Argentina Titulares

Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.

Pfizer-BioNTech booster targeting variants as safe as earlier COVID shots, 30-day data showsPfizer-BioNTech booster targeting variants as safe as earlier COVID shots, 30-day data showsPfizer and BioNTech have shown that their new bivalent COVID booster does what they hoped it would, with the same safety and side effect profile as earlier shots.
Leer más »

Pfizer study says updated COVID boosters rev up protectionPfizer study says updated COVID boosters rev up protectionPfizer says its updated COVID-19 booster significantly revved up adults' virus-fighting antibodies.
Leer más »

Pfizer-BioNTech bivalent booster shows higher immune response, but new COVID cases climb back above 40,000 a dayPfizer-BioNTech bivalent booster shows higher immune response, but new COVID cases climb back above 40,000 a dayUpdated trial data for Pfizer-BioNTech’s bivalent COVID booster showed a “substantially higher” immune response in adults than the original vaccine, the companies said.
Leer más »

China posts 6-month high COVID count as it sticks with strategyChina posts 6-month high COVID count as it sticks with strategyChina on Sunday reported its highest number of new COVID-19 infections in six months, a day after health officials said they were sticking with strict coronavirus curbs, likely disappointing recent investor hopes for an easing.
Leer más »



Render Time: 2025-04-04 23:46:59